FOCAL POINTS (Courageous Discourse)

FOCAL POINTS (Courageous Discourse)

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Semaglutide vs Tirzepatide for Weight Loss in Adults

Semaglutide vs Tirzepatide for Weight Loss in Adults

Large Prospective Comparative Data Find Edge with Tirzepatide

Peter A. McCullough, MD, MPH's avatar
Peter A. McCullough, MD, MPH
Aug 11, 2024
∙ Paid
85

Share this post

FOCAL POINTS (Courageous Discourse)
FOCAL POINTS (Courageous Discourse)
Semaglutide vs Tirzepatide for Weight Loss in Adults
23
8
Share
Upgrade to paid to play voiceover

By Peter A. McCullough, MD, MPH

The weekly injectable glucagon-like peptide GLP-1 agonists have been a substantial addition to the armamentarium for treatment of type 2 diabetes mellitus. Randomized trials demonstrating reductions in cardiovascular and chronic kidney disease outcomes have made this class of drugs even more attractive. However, nothing compares to the market and abuse potential than does the prospects of substantial weight loss for cosmetic reasons. I rarely prescribe this class of drugs for weight loss alone, however, when there are other medical problems present the benefits can outweigh the risks for many patients.

Keep reading with a 7-day free trial

Subscribe to FOCAL POINTS (Courageous Discourse) to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share